Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225115 | 0.87 | HTR6 (0.41) | GPR119USP30F11HDAC1HDAC2 | |
| SCHEMBL2225272 | 0.83 | STS (0.43) | GPR119USP30MGLLTP53 | |
| SCHEMBL25170898 | 0.81 | HDAC1 (0.45) | GPR119USP30HDAC1HDAC2TP53 | |
| SCHEMBL30368816 | 0.81 | HDAC1 (0.45) | GPR119USP30HDAC1HDAC2TP53 | |
| SCHEMBL2226286 | 0.81 | USP30 (0.39) | GPR119USP30 | |
| SCHEMBL2227314 | 0.80 | ESR2 (0.45) | GPR119USP30KMT2A | |
| SCHEMBL12518515 | 0.80 | GPR119 (0.48) | GPR119USP30TP53MEN1KMT2A | |
| SCHEMBL2227160 | 0.80 | USP30 (0.41) | GPR119USP30TACR1 | |
| SCHEMBL1012441 | 0.79 | TP53 (0.45) | GPR119MGLLTP53HPGDS | |
| SCHEMBL1012440 | 0.79 | TP53 (0.45) | GPR119MGLLTP53HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516445-B1 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2516445-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011087712-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP3A43, CYP3A7, CYP2C19 | GPR119 1673/4885USP30 4469/4885MGLL 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.